Inspire Medical Systems Inc. INSP

Inspire Medical Systems, Inc. operates as a medical technology company within the United States and select countries in Europe. The company develops and commercialises minimally invasive solutions for patients with obstructive sleep apnoea. Incorporated in 2007, Inspire has its headquarters in in Golden Valley, Minnesota.

Inspire has developed the first and only FDA-approved neurostimulation technology designed to treat moderate to severe obstructive sleep apnoea. The Inspire therapy monitors the patient's breathing and stimulates the hypoglossal nerve to ensure the airway is maintained. The system is suitable for patients that do not have a complete concentric collapse of the airway at the soft palate level or have significant central sleep apnoea.

Available on the NYSE, Inspire stock is listed under the ticker INSP. Inspire offers its system through a direct sales organisation to a range of ambulatory surgery centres and hospitals within the United States, as well as select countries within Europe. On 26th April, 2021, Inspire announced that it had reached an exclusive distribution agreement within Japan Lifeline Co., Ltd. Inspire's system received regulatory approval within Japan in 2018.

Keep up to date on the latest news and INSP share price movements by adding it to your eToro virtual portfolio.